Furthermore, somatic mutations have been retrieved in many cancer types (21), including CLL (22, 23), in which POT1 mutations were associated with reduced overall survival in patients treated with chemo-immunotherapy based on chlorambucil-rituximab or chlorambucil-obinutuzumab (24). The gene discussed is POT1; the disease is B-cell chronic lymphocytic leukemia.